{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:33:27Z","timestamp":1778643207902,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["U10EY023529"],"award-info":[{"award-number":["U10EY023529"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["U10EY023533"],"award-info":[{"award-number":["U10EY023533"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["U10EY023521"],"award-info":[{"award-number":["U10EY023521"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health, Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Thrombogenics"},{"DOI":"10.13039\/100000005","name":"Department of Defense (DoD) Defense Health Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.ajo.2017.10.008","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T15:52:24Z","timestamp":1508773944000},"page":"147-156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion"],"prefix":"10.1016","volume":"184","author":[{"given":"Ingrid U.","family":"Scott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal L.","family":"Oden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Ip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Blodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul C.","family":"VanVeldhuisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ajo.2017.10.008_bib1","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/archopht.1996.01100140443012","article-title":"Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study","volume":"114","author":"Mitchell","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2017.10.008_bib2","first-page":"133","article-title":"The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study","volume":"98","author":"Klein","year":"2000","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"2","key":"10.1016\/j.ajo.2017.10.008_bib3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2017.10.008_bib4","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/archopht.1993.01090080083022","article-title":"Baseline and early natural history report. The Central Vein Occlusion Study","volume":"111","year":"1993","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2017.10.008_bib5","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0161-6420(95)30848-2","article-title":"A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report","volume":"102","year":"1995","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2017.10.008_bib6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archopht.1997.01100150488006","article-title":"Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group","volume":"115","year":"1997","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2017.10.008_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ophtha.2016.09.038","article-title":"SCORE2 Report 2: study design and baseline characteristics","volume":"124","author":"Scott","year":"2017","journal-title":"Ophthalmology"},{"issue":"20","key":"10.1016\/j.ajo.2017.10.008_bib8","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1001\/jama.2017.4568","article-title":"Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion. The SCORE2 randomized clinical trial","volume":"317","author":"Scott","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ajo.2017.10.008_bib9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/archopht.116.2.227","article-title":"Identifying the content area for the 51-item National Eye Institute Vision Function Questionnaire (NEI-VFQ): results from focus groups with visually impaired persons","volume":"116","author":"Mangione","year":"1998","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2017.10.008_bib10","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1001\/archopht.116.11.1496","article-title":"Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI VFQ). NEI-VFQ Field Test Investigators","volume":"116","author":"Mangione","year":"1998","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2017.10.008_bib11","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-item National Eye Institute Visual Function Questionnaire","volume":"119","author":"Mangione","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"20","key":"10.1016\/j.ajo.2017.10.008_bib12","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.ajo.2017.10.008_bib13","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/bmj.314.7080.572","article-title":"Cronbach's alpha","volume":"314","author":"Bland","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.ajo.2017.10.008_bib14","series-title":"Resampling-Based Multiple Testing: Examples and Methods for P-Value Adjustment","author":"Westfall","year":"1993"},{"key":"10.1016\/j.ajo.2017.10.008_bib15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12886-016-0274-5","article-title":"Vision-targeted health related quality of life in older adults: patient-reported visibility problems in low luminance activities are more likely to decline than daytime activities","volume":"16","author":"Owsley","year":"2016","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2017.10.008_bib16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/09286580600864794","article-title":"Assessment of vision-related quality of life in an older population subsample: The Blue Mountains Eye Study","volume":"13","author":"Chia","year":"2006","journal-title":"Ophthalmic Epidemiol"},{"issue":"10","key":"10.1016\/j.ajo.2017.10.008_bib17","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.ophtha.2012.05.017","article-title":"Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials","volume":"119","author":"Varma","year":"2012","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2017.10.008_bib18","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2017.10.008_bib19","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ophtha.2012.01.042","article-title":"Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study","volume":"119","author":"Boyer","year":"2012","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2017.10.008_bib20","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2017.10.008_bib21","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ophtha.2014.08.031","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study","volume":"122","author":"Campochiaro","year":"2015","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2017.10.008_bib22","first-page":"1742","article-title":"Binocular visual acuity summation and inhibition in an ocular epidemiological study: the Los Angeles Latino Eye Study","volume":"43","author":"Azen","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.ajo.2017.10.008_bib23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/archopht.121.2.211","article-title":"National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS report no. 10","volume":"121","author":"Clemons","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2017.10.008_bib24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ajo.2004.09.028","article-title":"Vision-related quality of life in patients suffering from age-related macular degeneration","volume":"139","author":"Berdeaux","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2017.10.008_bib25","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1001\/archopht.117.12.1611","article-title":"Validity of the Visual Function Index (VF-14) in patients with retinal disease","volume":"117","author":"Linder","year":"1999","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2017.10.008_bib26","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/archopht.121.9.1297","article-title":"Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire","volume":"121","author":"Deramo","year":"2003","journal-title":"Arch Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939417304324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939417304324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:36:37Z","timestamp":1757597797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939417304324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":26,"alternative-id":["S0002939417304324"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2017.10.008","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2017.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}